CrossRef Text and Data Mining
Result of CrossRef Text and Data Mining Search is the related articles with entitled article. If you click link1 or link2 you will be able to reach the full text site of selected articles; however, some links do not show the full text immediately at now. If you click CrossRef Text and Data Mining Download icon, you will be able to get whole list of articles from literature included in CrossRef Text and Data Mining.
Phase I Dose-Finding Study of OPB-111077, a Novel STAT3 Inhibitor, in Patients with Advanced Hepatocellular Carcinoma
Changhoon Yoo, Jihoon Kang, Ho Yeong Lim, Jee Hyun Kim, Myung-Ah Lee, Kyung-Hun Lee, Tae-You Kim, Baek-Yeol Ryoo
Cancer Research and Treatment. 2019;51(2):510-518.   Published online 2018 June 13    DOI: https://doi.org/10.4143/crt.2018.226

Excel Download

Phase I Dose-Finding Study of OPB-111077, a Novel STAT3 Inhibitor, in Patients with Advanced Hepatocellular Carcinoma
Cancer Research and Treatment. 2019;51(2):510-518   Crossref logo
Link1 Link2 Link3

A First‐in‐Human Phase I Study of OPB‐111077, a Small‐Molecule STAT3 and Oxidative Phosphorylation Inhibitor, in Patients with Advanced Cancers
The Oncologist. 2018;23(6):658   Crossref logo
Link1 Link2 Link3

Phase 1 and pharmacological trial of OPB-31121, a signal transducer and activator of transcription-3 inhibitor, in patients with advanced hepatocellular carcinoma
Hepatology Research. 2015;45(13):1283-1291   Crossref logo
Link1 Link2

Phase 1, open-label, dose-escalation, and pharmacokinetic study of STAT3 inhibitor OPB-31121 in subjects with advanced solid tumors
Cancer Chemotherapy and Pharmacology. 2014;74(1):125-130   Crossref logo
Link1 Link2 Link3 Link4

Phase I Study of OPB-31121, an Oral STAT3 Inhibitor, in Patients with Advanced Solid Tumors
Cancer Research and Treatment. 2015;47(4):607-615   Crossref logo
Link1 Link2 Link3

Erratum to A phase II study of the efficacy and safety of the MET inhibitor capmatinib (INC280) in patients with advanced hepatocellular carcinoma
Therapeutic Advances in Medical Oncology. 2020;12:175883592091342   Crossref logo
Link1 Link2 Link3

A Phase (Ph) 1 dose finding study of X4P-001 (an oral CXCR4 inhibitor) and axitinib in patients with advanced renal cell carcinoma (RCC)
Annals of Oncology. 2017;28:v317-v318   Crossref logo
Link1 Link2 Link3

Pilot study: rapamycin in advanced hepatocellular carcinoma
Alimentary Pharmacology & Therapeutics. 2010;32(6):763-768   Crossref logo
Link1 Link2

A Phase I Dose-Finding Study of Silybin Phosphatidylcholine (Milk Thistle) in Patients With Advanced Hepatocellular Carcinoma
Integrative Cancer Therapies. 2013;13(1):46-53   Crossref logo
Link1 Link2 Link3

Re: Preliminary Results for Avelumab Plus Axitinib as First-Line Therapy in Patients with Advanced Clear-cell Renal-cell Carcinoma (JAVELIN Renal 100): An Open-label, Dose-finding and Dose-expansion, Phase 1b Trial
European Urology. 2019;75(4):697-698   Crossref logo
Link1 Link2

This metadata service is kindly provided by CrossRef from May 29, 2014. Cancer Res Treat has participated in CrossRef Text and Data Mining service since October 29, 2014.